SEC Form 4 · accession 0001562180-17-000883
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michel Dahan
Officer — SVP, Chief Business Officer
Period of report
Feb 21, 2017
Accepted (ET)
Feb 23, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 21, 2017 | A | 39,500 | $0.00 | A | 110,024 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F2 | $0.00 | Feb 21, 2017 | A | 62,500 | A | — | Feb 21, 2027 | Common Stock | 62,500 | 62,500 | D |
Explanation of responses
- F1The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date.
- F225% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.